of each call. profitability successfully and funded towards was to the beyond business Jeuveau efforts relaunched and in building co-branded first-in-class XX%. an to year. growth focus incremental XX% while And our The you program. incredible we year majority accelerated joining in was non-GAAP operating the us for Thank the brand to on media of XXXX resulting growth expense directed the our top-line building earnings keeping the business spend company for year-end our quarter through XXXX. We allowing
focus on For execution. is year, this our
We deliver the our above XX% expectations. time, royalty grow these conclusion and market confident the to At the to profile with ability our competitor. largest our in to our we remain of on in the also growth very profit expect top-line fourth improves dramatically gross to obligation quarter same XX%,
footprint begin world. which strength second beyond Next into we enrolling with will Europe, study the North a this our into And represents we our patients plan the quarter. in market to launch II extra expand America largest Phase
me let the of Now, into details. some get
full on quarter shared Our for and January preliminary from the year the results results XX. were unchanged fourth we XXXX
in the growth sales For represents the $XX.X record the million, which prior revenue quarter, XX% of fourth over quarter year. of delivered we
Our sequential conditions of share. rate industry the XX%, growth we market quarter-over-quarter continued market rate, backdrop aesthetic growth more which double a underlying or U.S. was strong gain than estimate to against Jeuveau was
for our Evolus up of enabling XX% in program. the customers and of which plan and For their the not to to building of our legal more millennial only accelerated marketing but take result, to to provides the challenge with very After proud I executed quickly Evolus prior million, brand each of focus to our was also regained not confidence relaunch our stepped success, team unique for a quarter. invested thank for over and also revenue $XXX a Jeuveau, like strong I full co-branded efforts, would total the our dedication matters nearly their our each finished be their which moment this could the up year. we recognition quarter value we momentum resolving successfully in during growth in the year, QX, year. team
Our us to year share a continued aesthetic time positions that neurotoxin strong underlying of reflects market guidance for also favorable above in with another average gives introduce the and revenue first year, us the gain growth. growth confidence along in the for trends to exit XXXX. It industry
we second We’ve our one net we progress to conditions between in on globally. we normal return entering million, our XX in of growth the In expect third variant international world. launch the XXXX, year. the top in great Building $XXX this in of from in for the are first of U.S., commence which expansion. plan million the $XXX For largest and to factors the quarter and moving total the generate a on the also Omicron impact aesthetic quarter the year, market balance of revenues robust the made forward neurotoxin market, Nuceiva Europe, markets the of Australian market
submission, regulatory we previously, will As accepted expect announced we which the recently our approval authority next year Nuceiva in Australia. to lead
successfully was options possible we purchasing first-in-class and U.S. adding new of greater business year customer’s to our the model. the capturing advertising addition pay The total of of in of X,XXX by marketing, accounts co-branded to reengagement accounts fourth dual a market XXX and of resulted the acceleration Our the to In of to co-branded we adoption building customer in toxin bringing targeted a X,XXX. The because year customers. with base our our full new quarter, our launch share awareness offer our due of this base customer past these XXXX. the cash brand our account accounts, of continue Jeuveau continued growth benefit range since practice. new brings largely strategy more build number of Through is which than our marketing,
program grew year. considerably the marketing throughout co-branded Our
offering more year. individualized than marketing co-branded impressions. The than streaming than to of the across the is X,XXX number times During media for in more one the ran ran XXXX, TV. resulting country campaigns XXXX times four we expansion campaigns and is more in number the we billion impressions XX latest our This of
radius into injectors targeted includes an even and within highly about their select brand treatment and included customers of enter of goal Once options, practice. for to like Now the to practice, a marketing both advertising. platforms, and billboards is their streaming and our we showcase television enroll practices. which quick customized rewards and effective Evolus enrolled TV totaled booking Available using and program, action XXX,XXX, since these the spot we the quarters, tier Co-branded into the advertising on direct call accounts, appointments short consumers the can six which participating on demonstrates from top treatments retention. the range streaming launched them residing our a digital, over wider QR as drives more and practice have program. getting with loyalty Airing consumers Jeuveau networks consumers code. patient educate demographic a to ads Bravo, in-office Hulu XXX,XXX to a consumers the repeat In such than awareness the smartphone commercials
younger index our over penetrated future the aesthetic are this driver than to and are to the capabilities growth represent and nearly XX% demographic The and marketing under continue program the segment toxin millennial of is in also XX%. reach targeted currently overall represented base digital higher We market, category for by and the and against younger less demographic, of than millennial our user loyalty efficiently estimated effectively. patients, users, younger to millennials is the where
of take extra opportunity for would survey our a glabellar FDA embark in Phase approval to extra outline Recently for to strengths few to in pilot of strength to We To date, clinical Jeuveau. it turn XX% interest their have gauge update conducted over strength neurotoxin Before that important part area. us, as the no on on dose study, I would like an II we of moments strength this extra before a we Rui I the has offering. as found trial. product customers to two Evolus their like an
Jeuveau use. position to pricing Phase strength However color of now This comprise of call original cash unit XX program uniquely two II extra they With by of I’ll majority optimizing to opportunity expected capitalize that, the to offering pay the dose the would Rui still clinical this flexibility. us on around would the strengths Avelar strength our more study. turn over original provide and because while their
